Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Statistics in Medicine|May 24, 2005
Dose escalation trial designs based on a molecularly targeted endpointSally Hunsberger, Lawrence V Rubinstein, Janet Dancey, et al.Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd, Edward L Korn, Boris Freidlin, et al.Cancer Informatics|April 11, 2015
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical TrialsYingdong Zhao, Eric C Polley, Ming-Chung Li, et al.Journal of Oncology Practice|October 5, 2018
What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?Katherine V Ferry-Galow, Vivekananda Datta, Hala R Makhlouf, et al.The Journal of Molecular Diagnostics : JMD|November 26, 2015
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT TrialChih-Jian Lih, David J Sims, Robin D Harrington, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.Frontiers in Oncology|June 3, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft modelsYvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, et al.JCO Precision Oncology|April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II TrialAlice P Chen, Shivaani Kummar, Nancy Moore, et al.Pageof 2